ACT 2001 / Alden Cancer Therapy II, Haakon Ragde Foundation - LARVOL DELTA

[VIRTUAL] Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC) (EAU-I 2020) - P1 | "Dose escalation by 3 + 3 design (n=9) and dose expansion combined with checkpoint inhibitor (ipilimumab (n=6) or pembrolizumab (n=3)) were performed. CryoIT has an adequate safety profile and is well tolerated. Higher median PSA for RG2 at inclusion could imply more advanced or aggressive disease. New TCR clonotypes following CryoIT suggest immunologic treatment responses."

Checkpoint inhibition • Clinical • P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • MRI

Dendritic cell (DC) based cryoimmunotherapy (CryoIT) in a prospective phase I trial of metastatic castration resistant prostate cancer (mCRPC): Interim analysis. (ASCO 2018) - P1; "The treatment seems safe and well tolerated. Higher PSA at baseline suggests more advanced disease in Group 2. The data indicate immune responses to treatment with higher increases in TCR clonotypes in men with radiologic stable disease."

Clinical • P1 data • Prostate Cancer

[VIRTUAL] A prospective phase I trial of dendritic cell-based cryoimmunotherapy in metastatic castration-resistant prostate cancer. (ASCO 2020) - P1 | "DC treatment seems safe and well tolerated, also combined with checkpoint inhibitors. Effect is indicated in subjects with moderate pre-treatment PSA levels. Immune responses are suggested by higher number of novel TCR clonotypes in men with non-progressive disease."

Clinical • IO Biomarker • P1 data • Anesthesia • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CTCs

Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC) (EAU 2020) - No abstract available

Checkpoint inhibition • Clinical • P1 data

CryoIT: Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: Alden Cancer Therapy II; Recruiting ➔ Completed; Trial completion date: Apr 2019 ➔ Aug 2019; Trial primary completion date: Dec 2018 ➔ Aug 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date